Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist developed using the company’s proprietary technology platform for the treatment of life-threatening hypoglycemic episodes associated with post-bariatric hypoglycemia (PBH).